Related Experiment Videos
Intracavitary chromic phosphate (32P) colloidal suspension therapy
Cancer
|December 15, 1981
Summary
Chronic phosphate (32P) colloidal suspension (CPCS) therapy showed significant improvement in patients. Intraperitoneal treatments yielded 85% improvement, while intrapleural treatments showed 75% improvement in patients who survived three months.
Area of Science:
- Radiology
- Oncology
- Nuclear Medicine
Background:
- Chronic phosphate (32P) colloidal suspension (CPCS) has been utilized in patient treatment since 1963.
- A significant number of patients have undergone CPCS therapy, with various administration routes documented.
Purpose of the Study:
- To evaluate the therapeutic outcomes of chronic phosphate (32P) colloidal suspension (CPCS) treatments.
- To assess the efficacy of intraperitoneal and intrapleural CPCS administration in improving patient conditions.
Main Methods:
- A retrospective analysis of 289 patients treated with 346 administrations of CPCS since 1963.
- Treatments included intraperitoneal (200 instances), intrapleural (144 instances), and combined routes.
- Patient outcomes were assessed at three months and annually thereafter.
Main Results:
- Therapy results were evaluated in patients surviving the initial three months post-treatment.
- Physician-observed improvement was noted in 85% of intraperitoneal CPCS treatments.
- Physician-observed improvement was noted in 75% of intrapleural CPCS treatments.
Conclusions:
- Chronic phosphate (32P) colloidal suspension (CPCS) demonstrates considerable therapeutic benefit in patient management.
- Intraperitoneal administration of CPCS appears to yield higher rates of observed improvement compared to intrapleural administration.